Clinical Trial Update: Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Anti T-lymphocyte Immunoglobulin with post-transplant cyclophosphamide to prevent GVHD after allogeneic transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Anti T-lymphocyte Immunoglobulin
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Sheba Medical Center | Conditions: Graft Versus Host Disease | Phase 2 | Status: UNKNOWN